Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s share price dropped 0% on Friday . The company traded as low as $10.67 and last traded at $10.84. Approximately 999,930 shares were traded during mid-day trading, an increase of 138% from the average daily volume of 419,694 shares. The stock had previously closed at $10.84.
SNDX has been the topic of a number of research analyst reports. ValuEngine raised shares of Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 20th. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, January 5th. Morgan Stanley cut their price target on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Wednesday, March 14th. B. Riley initiated coverage on shares of Syndax Pharmaceuticals in a report on Friday, January 5th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, BidaskClub raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $23.86.
The firm has a market capitalization of $361.33, a price-to-earnings ratio of -3.74 and a beta of 1.13.
In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 7,500 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total transaction of $112,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 24.10% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. HighPoint Advisor Group LLC purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at about $102,000. Trexquant Investment LP bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $133,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $154,000. Dimensional Fund Advisors LP bought a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at about $192,000. Finally, California State Teachers Retirement System increased its position in shares of Syndax Pharmaceuticals by 60.9% during the second quarter. California State Teachers Retirement System now owns 15,587 shares of the company’s stock valued at $218,000 after buying an additional 5,900 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.